Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
COMPASS Pathways
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- ACTIVE_NOT_RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 572
- sponsor
- COMPASS Pathways
- conditions
- Treatment Resistant Depression
- interventions
- DRUG: Psilocybin
- start date
- 2023-02-14
- start date type
- ACTUAL
- primary completion date
- 2025-11-13
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT05711940
- Published
- Feb 3, 2023
- Updated
- Aug 10, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT05711940
- Categories
- Treatment Resistant Depression
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials